Acceptance Rate


Time to first decision

8 days*

Time from acceptance to publication

13 days*

Impact Factor (JCR):


Impact Factor rank (JCR):




Aims and Scope

Annals of the Rheumatic Diseases (ARD) is an international peer review journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research.

Annals of the Rheumatic Diseases is the flagship of BMJ’s rheumatology portfolio and has two companion journals: RMD Open for original research in rheumatology and musculoskeletal disorders and Lupus Science & Medicine for original research in lupus and related diseases.

For information about the Annals of the Rheumatic Diseases Editor-in-Chief Prof Josef Smolen and his editorial team, please refer to the Editorial Board page.

Plan S compliance

Annals of the Rheumatic Diseases is a Plan S compliant Transformative Journal. Transformative Journals are one of the compliance routes offered by cOAlition S funders, such as Wellcome, WHO and UKRI. Find out more about Transformative Journals and  Plan S compliance on our Author Hub.

Journal Information

Ownership ARD is co-owned by the European Alliance of Associations for Rheumatology (EULAR) and BMJ.
Publication Model Subscription; with hybrid open access option
Frequency Monthly
Launch date 1939
Digital Archives Portico, LOCKSS
Indexed by Web of Science Core Collection: Science Citation Index, Science Citation Index Expanded; BIOSIS Previews, Current Contents: Clinical Medicine, Life Sciences; MEDLINE (Index Medica), PubMed Central (BMJ Open Access Special Collection), Scopus, Embase (Excerpta Medica), CINAHL, Google Scholar
Peer Review Model Single blind; the names of reviewers are hidden from the author
Print ISSN 0003-4967
Online ISSN 1468-2060

Journal Statistics (2020)

Acceptance rate: 27%

Time to first decision: 8 days (mean)
Time from acceptance to publication: 13 days (mean)

Impact Factor category: Rheumatology
Impact Factor (JCR): 19.103
Impact Factor rank: 2/34
5 Year Impact Factor: 17.075
Journal Citation Indicator (JCI): 3.82
Eigenfactor: 0.06443
Citescore: 28.7
Citescore rank: 1/56
Scimago Journal rank (SJR): 6.333

2020 total content views: 2,030,945
2020 total Altmetric mentions: 11,299

The impact that academic research has cannot be defined by one single metric. In 2013, BMJ signed the San Francisco Declaration on Research Assessment (DORA). We did this to show our support for using multiple measures and metrics to portray journals’ impact; moving away from the Impact Factor as a single measure.

How we get these metrics

Contact Information

For all contact information please refer to the Contact Us page.

For Authors

Please refer to the Instructions for Authors.


To advertise

Rights and Permissions


ARD is the official journal of European Alliance of Associations for Rheumatology (EULAR) and all (scientific) delegates to the annual EULAR congress receive a complimentary 12 month subscription to the journal.
COPE logo

BMJ is a founding member of COPE (the Committee on Publication Ethics), which provides a forum for publishers and Editors of scientific journals to discuss issues relating to the integrity of the work submitted to or published in their journals.


The EQUATOR Network is an international initiative that seeks to improve the value of medical research literature by promoting transparent, accurate reporting of research studies. BMJ is a sponsor of its activities.

AllTrials logo

BMJ is a founding organisation of the AllTrials initiative, which calls for all past and present clinical trials to be registered and their results reported.